Skip to main content
. 2019 Nov 22;9:1271. doi: 10.3389/fonc.2019.01271

Table 1.

Summary of rhabdomyosarcoma (RMS) preclinical studies for PLK1 inhibitors combined with other drugs.

PLK1 inhibitor Combination partner RMS cell line models Result (CI = Combination Index) References
BI2536 Vincristine In vitro RD, TE381.T (fusion-negative) Primary RMS cells (fusion-negative) CI <1.0 and synergy in various assays (41)
Rh30 (fusion-positive) CI <1.0 (41)
Volasertib Vincristine RD, TE381.T CI <1.0 (41)
Volasertib Vincristine RMS1 (fusion-positive) CI <1.0 (28)
BI2536 Vincristine in vivo RD cells grown in chorioallantoic membrane model At least additive effects (41)
Volasertib Vincristine RD xenograft s.c. in mice At least additive effects (41)
BI2536 Vinblastine/vinorelbine RD (fusion-negative) CI <1.0 (41)
BI2536 Eribulin RD, TE381.T (fusion-negative), patient-derived fusion negative cells CI <1.0, synergy in several assays (42)
Rh30 (fusion-positive) CI > 1.0 (42)
BI2536 Paclitaxel RD (fusion-negative) CI > 1.0 (41)
BI2536 Doxorubicin RD, TE381.T (fusion-negative), Rh30 (fusion-positive) CI > 1.0 (41)
Volasertib Etoposide RMS1 (fusion-positive) CI > 1.0 (28)